Illumina's Flatley Discusses Future Diagnostics Path, Array Roadmap at Goldman Sachs Conference | GenomeWeb

By Justin Petrone

Illumina believes its arrays will be used "routinely for medical management" in coming years and has seen "very significant uptake" for its next generation of Omni BeadChips, according to its highest official.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.